

## **Allina Health's Abbott Northwestern Hospital is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure**

MINNEAPOLIS, Jan. 29, 2024 – CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) and Allina Health are pleased to announce that a team at Allina Health's Abbott Northwestern Hospital has successfully completed the first Barostim™ Baroreflex Activation Therapy implant in the state of Minnesota.

75-year-old James Bennett of Brainerd, Minnesota has had three heart attacks in the last three years, which led to congestive heart failure.

“I felt weak and tired all the time and knew I didn't want to spend my life sitting in the living room chair. When my doctor recommended Barostim and gave me the option to feel better, I was ready for a change,” said Bennett.

The procedure was performed by Jeffrey Jim, MD, FACS, Chair of Vascular and Endovascular Surgery, and referred by Peter Eckman, MD, Heart Failure Section Head, at Allina Health.

“Not only are we proud to be offering Barostim at Abbott Northwestern Hospital, but we are excited to be the first hospital in the state of Minnesota to make this novel therapy available for heart failure patients,” said Dr. Eckman. “With this milestone, more patients now have access to a treatment option to help reduce their heart failure symptoms and improve their quality of life when medications alone are not enough.”

Following the implant and subsequent clinical follow-ups with his physician, Bennett has begun to feel symptom improvements from the therapy. “My wife and I have 3.5 acres of land and, since receiving Barostim, I'm back mowing. I'm able to do yardwork, get outside and spend time being active,” said Bennett, a father of three and grandfather of eight.

Barostim, the world's first FDA-approved neuromodulation heart failure device, works by stimulating baroreceptors – natural sensors located in the wall of the carotid artery – that tell the nervous system how to regulate heart, kidney and vascular function. These effects may reduce the heart's workload and help it pump more efficiently, improving the heart failure symptoms of patients with systolic heart failure.

"Congratulations to Dr. Jim, Dr. Eckman and Abbott Northwestern Hospital on successfully completing this first implant procedure of Barostim," said Nadim Yared, President and CEO of CVRx. "We value our collaboration with them and commend their ongoing efforts to advance the treatment of heart failure symptoms."

This procedure also marks the first Barostim implant for CVRx on the home front. The company received FDA approval for Barostim in August 2019, and now adds Allina Health's Abbott Northwestern Hospital to its growing, active total implanting sites throughout the U.S. of 178.

**About CVRx, Inc.**

CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit [www.cvr.com](http://www.cvr.com).

**About Allina Health**

Allina Health is dedicated to the prevention and treatment of illness and enhancing the greater health of individuals, families and communities throughout Minnesota and western Wisconsin. A nonprofit health care system, Allina Health cares for patients from beginning to end-of-life through its 90+ clinics, 12 hospital campuses, 14 retail pharmacies, and many specialty care centers and specialty medical services, home care, and emergency medical transportation services. Learn more at [allinahealth.org](http://allinahealth.org).

**CVRx Media Contact:**

Laura O'Neill  
Finn Partners  
402-499-8203  
[laura.oneill@finnpartners.com](mailto:laura.oneill@finnpartners.com)

**CVRx Investor Contact:**

Mark Klausner or Mike Vallie  
ICR Westwicke  
443-213-0501  
[ir@cvrx.com](mailto:ir@cvrx.com)

**Allina Media Contact:**

Jenny Griswold Steingas  
612-388-1895  
[jennifer.steingas@allina.com](mailto:jennifer.steingas@allina.com)